Absci Corporation (ABSI)
ABSINASDAQ-GSBiotechnology: Commercial Physical & Biological Resarch
$8.49
-0.6450 (-7.06%) today
Regular session, Nov 13, 12:13 PM ET
- Market cap
- $1.47bn
- P/E
- –
- EPS, last 4 quarters
- $-0.8000
- Dividend yield
- –
- Day range
- $8.32 to $9.40
- 52-week range
- $2.24 to $12.54
- Average volume
- –
- Previous close
- $9.14
Analysts
10 coveringBuy9 buy, 1 hold, 0 sell
Targets a year out average $14.75, +73.7% from here
Earnings
next estimate $-0.1800Next report
Dec 2025
-43.8%
Mar 2026
+5.0%
Jun 2026
–
Sep 2026
-21.4%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $650.0k | $215.0k | $318.0k | $304.0k |
| Gross profit | $650.0k | $215.0k | $318.0k | $304.0k |
| Operating income | -$31.04m | -$30.85m | -$34.16m | -$34.99m |
| Net income | -$29.56m | -$29.60m | -$33.21m | -$33.30m |
Last four quarters: revenue $1.49m, margin -8451.3%, free cash flow -$112.46m
News
8 latest- Absci Corporation Reports Third Quarter 2026 Financial Results and Clinical Pipeline UpdatesFintel · 14 hours ago
- Absci (ABSI) Q3 2026 Earnings Call TranscriptThe Motley Fool · 1 day ago
- Absci Q3 Earnings Call HighlightsMarketBeat · 1 day ago
- Absci Corporation (ABSI) Reports Q3 Loss, Misses Revenue EstimatesZacks · 1 day ago
- Absci Corp Q3 Sales Decline RTTNews · 1 day ago
- Scholar Rock Holding Corporation (SRRK) Reports Q3 Loss, Beats Revenue EstimatesZacks · 3 days ago
- Verastem (VSTM) Reports Q3 Loss, Misses Revenue EstimatesZacks · Nov 5, 2026
- Jefferies Initiates Coverage of Absci with BuyFintel · Oct 30, 2026
The company
Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci's approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics including ABS-201, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for pattern hair loss.
- Sector
- Health Care
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- absci.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.